Metabolic conditions — research evidence maps

Research evidence map for type 2 diabetes (T2D): incretin medicines, cardiovascular and kidney outcome trials, and the major UK clinical-pathway questions.

5 molecule(s) · 5 trial(s) · 4 safety signal(s)

Research evidence map for obesity: the SCALE, STEP, SURMOUNT and Phase 2 retatrutide weight-management programmes, dose-response and discontinuation data, and UK MHRA/NICE positioning.

4 molecule(s) · 6 trial(s) · 3 safety signal(s)

Research evidence map for prediabetes (impaired fasting glucose, impaired glucose tolerance, HbA1c in the prediabetic range) and the role of incretin medicines in preventing or delaying progression to type 2 diabetes.

3 molecule(s) · 3 trial(s) · 2 safety signal(s)

Research evidence map for metabolic syndrome — the cluster of abdominal obesity, dyslipidaemia, hypertension and dysglycaemia — and the integrated effects of incretin medicines across its components.

3 molecule(s) · 3 trial(s) · 3 safety signal(s)

Research evidence map for MASLD and its progressive form MASH (formerly NAFLD/NASH): hepatic steatosis quantification by MRI-PDFF, biopsy endpoints, and incretin / dual-agonist trial data in MASH.

5 molecule(s) · 1 trial(s) · 2 safety signal(s)

Research evidence map for OSA in adults with obesity: AHI severity, polysomnographic endpoints, and the SURMOUNT-OSA tirzepatide trial that established a registerable AHI reduction endpoint.

2 molecule(s) · 1 trial(s) · 1 safety signal(s)

Research evidence map for HFpEF in adults with obesity: SUMMIT trial of tirzepatide and the Kansas City Cardiomyopathy Questionnaire endpoint.

2 molecule(s) · 1 trial(s) · 2 safety signal(s)

Research evidence map for cardiovascular outcomes with incretin medicines: SELECT, SURPASS-CVOT, LEADER, SUSTAIN-6, REWIND, SUMMIT and the FLOW kidney-outcome trial.

4 molecule(s) · 5 trial(s) · 1 safety signal(s)

Research evidence map for CKD in T2D: FLOW kidney-outcome trial of semaglutide, eGFR-slope endpoints, and the cardio-renal-metabolic intersection.

2 molecule(s) · 3 trial(s) · 2 safety signal(s)

Research evidence map for HIV-associated lipodystrophy: tesamorelin (Egrifta) as the US-licensed GHRH analogue for excess visceral adipose tissue in HIV.

1 molecule(s) · 0 trial(s) · 0 safety signal(s)

Research evidence map for visceral adipose tissue (VAT) as a cardiometabolic risk driver and a target of incretin and GH-axis therapy.

4 molecule(s) · 2 trial(s) · 1 safety signal(s)

Research evidence map for the lean-mass component of weight reduction with incretin therapy, especially in older adults and those with low baseline muscle mass.

3 molecule(s) · 2 trial(s) · 1 safety signal(s)

Research evidence map for the maintenance phase: durability of weight reduction with continued incretin therapy and outcomes after discontinuation.

2 molecule(s) · 2 trial(s) · 1 safety signal(s)

Research evidence map for the post-discontinuation trajectory: SURMOUNT-4 randomised-withdrawal data, STEP 1 follow-up, and the clinical implications of stopping therapy.

2 molecule(s) · 2 trial(s) · 1 safety signal(s)

Research evidence map for polycystic ovary syndrome (PCOS) and the metabolic overlap with insulin resistance, obesity and cardiometabolic risk, including emerging GLP-1 receptor agonist evidence.

3 molecule(s) · 2 trial(s) · 3 safety signal(s)